

## Prevention & Treatment of Hepatitis and Chronic Liver Disease

Costa Mesa, CA – May 14, 2022

**Conference  
Location**

**Hilton Orange County-Costa Mesa**  
3050 Bristol Street  
Costa Mesa, California 92626

**Phone: (714) 540-7000**

<https://www.hilton.com/en/hotels/snacmhh-hilton-orange-county-costa-mesa>

**Parking at the  
Conference**

Discounted Self-Parking of \$10,00 per day has been arranged for all participants.

Please bring your parking ticket to the seminar registration desk to receive this rate

**Driving  
Directions**

Follow I-405 N or S to Bristol Street in Costa Mesa.

Continue on Bristol Street going West.

Just before you reach Paularino Avenue, the hotel will be on your left.

**Seminar Agenda  
and Syllabus  
Information**

Registration begins at **7:00 a.m.** in the **Newport Ballroom** Please check signage for any last-minute room changes.

**The Hepatitis and Chronic Liver Disease seminar** is a paperless program. The **course syllabus and related materials will be made available on a digital app** that can be accessed by a smart phone, tablet or personal computer. Instructions to download the *App* will be provided. Wi-Fi will be available without charge.

<b>Pre-Program Activities</b>	<b>Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min <b>Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
<b>7:00am</b>	<b>Registration and View Exhibits</b>
<b>7:30 am</b>	<b>Opening Comments and Pre-Test</b>
<b>7:45 am</b>	<b>Hepatitis C: Update on Diagnostics</b> <ul style="list-style-type: none"> <li>• Short recap of key points from Pre-course lecture on viral hepatitis</li> <li>• Screening and diagnostic approaches of HCV</li> </ul> <b>Hepatitis C: Update on Treatment</b> <ul style="list-style-type: none"> <li>• AASLD/IDSA Guidelines and Updates</li> <li>• Simplified Guidance</li> </ul> <b>Case Studies 1 and 2</b> –New Case relevant to diagnosis and treatment of high-risk HCV patient
<b>8:35am</b>	<b>Hepatitis B: Epidemiology, Natural History and Testing</b> <ul style="list-style-type: none"> <li>• The epidemiology of the Hepatitis B infection</li> <li>• Efficacies and opportunities in HBV testing and vaccination</li> </ul> The growing relationship between HBV and HDV
<b>9:05 am</b>	<b>Anti-viral Therapies for HBV</b> <ul style="list-style-type: none"> <li>• Early detection and treatment approaches</li> <li>• Treating HCC in patients with Hepatitis B</li> </ul> Reactivation of HBV
<b>9:35 am</b>	<b>Industry Presentation #1 Break and View exhibits</b>

<b>10:15 am</b>	<b>Delta Hepatitis and Hepatitis E Update</b> <ul style="list-style-type: none"> <li>Worldwide perspective and promising research studies</li> <li>Real world outcome studies on HDV and HEV</li> </ul>
<b>10:45 am</b>	<b>End Stage Liver Disease: Recap and Clinical Case</b> <ul style="list-style-type: none"> <li>A review of Pre-course lecture touching on staging, work-up and remedies for cirrhosis and the liver transplant process</li> </ul>
<b>11:15 am</b>	<b>Alcoholic Liver Disease</b> <ul style="list-style-type: none"> <li>The growing prevalence of alcohol over-consumption and its impact on liver health</li> <li>Warning signs and intervention in alcoholic hepatitis</li> </ul>
<b>11:45 am</b>	<b>Hepatocellular Carcinoma (HCC)</b> <ul style="list-style-type: none"> <li>Screening diagnostic serum assays and imaging tests</li> <li>Treatment and management options: Ablation, TACE and Surgery</li> </ul>
<b>12:15 pm</b>	<b>Luncheon and Industry Presentation #2</b>
<b>1:00pm</b>	<b>Dessert and View Exhibits</b>
<b>1:10 pm</b>	<b>Hepatocellular Carcinoma: New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>Current FDA-Approved Therapies</li> <li>New chemotherapy regimens in development and testing</li> <li>Immunotherapy as the new MoA for HCC</li> </ul> <b>Case Study 3– Diagnosis and Treatment of Hepatocellular Carcinoma</b>
<b>1:40 pm</b>	<b>SARS-COV-2 in Liver Disease</b> <ul style="list-style-type: none"> <li>Effect of COVID on the liver and in cirrhotic patients</li> <li>COVID-19 challenges for liver transplant recipients</li> </ul>
<b>2:10pm</b>	<b>Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis</b> <ul style="list-style-type: none"> <li>Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>Predicting outcomes and Improving Survival in PSC patients</li> <li>Causes and Markers of PBC</li> <li>Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> </ul>
<b>2:45 pm</b>	<ul style="list-style-type: none"> <li><b>Break &amp; View Exhibits</b></li> </ul>
<b>3:00 pm</b>	<b>NAFLD and NASH</b> <ul style="list-style-type: none"> <li>Epidemiology, Demographics and Diagnosis</li> <li>Scoring, Staging and Management of Fatty Liver Disease</li> <li>Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> </ul>
<b>3:35 pm</b>	<b>NASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>Current therapies for NASH including Updates from AASLD and EASL</li> <li>Lifestyle changes as a therapy</li> <li>Drugs in clinical development for NASH</li> </ul>
<b>4:25 pm</b>	<b>Closing Comments, Post-test and Wrap-Up</b> Program adjourns at 4:45 pm
<b>Post-program activities</b>	<b>Lecture 3 - Viral Hepatitis Updates: The reemergence of Hepatitis A and Overcoming barriers to liver health in special populations - 60 minutes</b>

---

**Attendance  
Policies****Attendee Cancellation, Substitution, Refund**

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

**Recording and Photography**

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

**Guest Attendance**

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

**Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---

**CME  
Information**

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1264. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME.



**TSE-LING FONG, MD**

Dr. Tse-Ling Fong is Associate Professor of Medicine and former Medical Director of the USC Liver Transplantation Program. Dr. Fong obtained his medical degree from the University of Southern California.

A long standing member of American Association for the Study of Liver Disease, he was elected Fellow (inaugural class) in 2014. Since 2002, he has been named every year to “Best Doctors in America” distinction. He has published extensively in chronic hepatitis B, hepatitis C, liver transplantation and drug-induced liver injury.



**MAZEN NOUREDDIN, MD, MHSC,**

Dr. Mazen Nouredin, MD, MHSc, is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center. He is a faculty at the Division of Digestive and Liver Diseases which was ranked #2 in gastroenterology and gastrointestinal surgery in the 2019 US News and World report. His focus is on clinical and translational research in the area of NAFLD.

Dr. Nouredin has conducted more than 30 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, transient elastography, and magnetic resonance imaging techniques. He is a member of the Liver Forum (FDA-AASLD-Academic Colloquium), standardizing pathways to translate therapeutic agents to clinical practice. He was one of the authors who established MRI-PDFF as a precise biomarker for measurement of liver fat in patients with NAFLD/ NASH.



**TAMMY HARPER, NP-C**

Tammy Harper received her undergraduate degree at Union University in Tennessee and her Masters Degree in nursing from the University of California in Los Angeles. Tammy Harper joined the UCS Keck Scholl of Medicine team in 2013, after 14 years of practicing internal medicine. Her clinical interest and expertise are in chronic liver disease and liver transplantation.

Tammy has participated in research studies related to Hepatitis C infections, including Detection of Occult Hepatitis C virus Infection in Patients Who Achieved Sustained Virologic Response to Direct Acting Antiviral Agents for Recurrent Infection After Liver Transplantation. Published in The Journal of Gastroenterology in 2017, and abstract accepted to AASLD in 2016.

Professionally, Tammy is an associate member of the American Association for the Study of Liver Disease, and the Co-Chair of the Southern California Society of Gastroenterology Nurses Course.